Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $130.10 million
- Book Value:
- Revenue TTM:
- $41.90 million
- Operating Margin TTM:
- Gross Profit TTM:
- $41.80 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Affimed NV had its IPO on 2014-09-12 under the ticker symbol AFMD.
The company operates in the Healthcare sector and Biotechnology industry. Affimed NV has a staff strength of 197 employees.
Shares of Affimed NV opened at $0.78 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $0.74 - $0.82, and closed at $0.76.
This is a -1.94% slip from the previous day's closing price.
A total volume of 977,700 shares were traded at the close of the day’s session.
In the last one week, shares of Affimed NV have slipped by -11.32%.
Affimed NV's Key Ratios
Affimed NV has a market cap of $130.10 million, indicating a price to book ratio of 0.9232 and a price to sales ratio of 3.7958.
In the last 12-months Affimed NV’s revenue was $41.90 million with a gross profit of $41.80 million and an EBITDA of $-81228000. The EBITDA ratio measures Affimed NV's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Affimed NV’s operating margin was -195.84% while its return on assets stood at -22.46% with a return of equity of -48.04%.
In Q3, Affimed NV’s quarterly earnings growth was a positive 0% while revenue growth was a positive 68.7%.
Affimed NV’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.64 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Affimed NV’s profitability.
Affimed NV stock is trading at a EV to sales ratio of 2.1985 and a EV to EBITDA ratio of 0.5331. Its price to sales ratio in the trailing 12-months stood at 3.7958.
Affimed NV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $236.40 million
- Total Liabilities
- $40.83 million
- Operating Cash Flow
- $2.16 million
- Capital Expenditure
- Dividend Payout Ratio
Affimed NV ended 2023 with $236.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $236.40 million while shareholder equity stood at $181.10 million.
Affimed NV ended 2023 with $0 in deferred long-term liabilities, $40.83 million in other current liabilities, 1493000.00 in common stock, $-392826000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $222.90 million and cash and short-term investments were $222.90 million. The company’s total short-term debt was $5,498,000 while long-term debt stood at $13.03 million.
Affimed NV’s total current assets stands at $230.55 million while long-term investments were $0.00 and short-term investments were $0. Its net receivables were $1.69 million compared to accounts payable of $15.08 million and inventory worth $673000.00.
In 2023, Affimed NV's operating cash flow was $2.16 million while its capital expenditure stood at $99000.
Comparatively, Affimed NV paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Affimed NV stock is currently trading at $0.76 per share. It touched a 52-week high of $5.1 and a 52-week low of $5.1. Analysts tracking the stock have a 12-month average target price of $7.56.
Its 50-day moving average was $1.04 and 200-day moving average was $2 The short ratio stood at 2.25 indicating a short percent outstanding of 0%.
Around 360.3% of the company’s stock are held by insiders while 6380.6% are held by institutions.
Frequently Asked Questions About Affimed NV
Similar Industry Stocks (Biotechnology)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Artiva Biotherapeutics Inc., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.